FirstWord

Gilead is using Nucleai AI's Tissue Intelligence platform to better understand why some patients respond to antibody-drug conjugates and others do not.

Financing will support training of foundation models and expansion of the Lab-in-the-Loop engine.

Bios Life has partnered with Tempus to help train and validate its predictive models.

The PGDx elio tissue complete CDx is designed to help identify patients whose tumours carry BRAF V600E or V600K variants.

The co-innovation hub pairs AWS engineers and AI specialists with Novo Nordisk's R&D teams to boost productivity and reduce the time to market for future medicines.

University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...

Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to ...

Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...

Second Quarter Revenue Growth of 52% to $132 MillionRaises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionBRISBANE, Calif.--(BUSINE...

Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and ScreeningRaises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Cali...